NICE threshold increase: the strategic questions your pricing team should be asking

Yesterday, the UK government announced a major change in pharmaceutical pricing policy. NICE’s cost-effectiveness threshold will…

Yesterday, the UK government announced a major change in pharmaceutical pricing policy. NICE’s cost-effectiveness threshold will…

Dynamic or Adaptive pricing: Aligning value and access across the lifecycle.

Price transparency in high-cost therapies: striking a balance between innovation and access

Moving away from the decentralized manner in which Health Technology Assessments (HTAs) have been conducted, Joint Clinical Assessment (JCA) aims to streamline HTA processes, minimize duplication of HTA body efforts, enhance efficiencies, accelerate access to medicines, and, ultimately, support EU member states in their national HTA processes.

Tariffs, Trade, and Turbulence: Navigating Pharmaceutical Pricing and Supply Chain Risk in an Era of Protectionism

Innovative treatments call for innovative pricing models and access solutions. With ever more novel and costly…

The pharmaceutical industry is increasingly under pressure to bring innovative therapies to market quickly. Early clinical…

he definition of women’s health is often misinterpreted, with the common misconception that women’s health only concerns female-specific conditions such as fertility, gynecological conditions, and women’s oncology. There are, however, many conditions which affect women differently (cardiovascular diseases) or disproportionately (autoimmune diseases, migraines, osteoporosis) which are often under-recognized by the healthcare industry and health systems.2

As we stand at the threshold of a transformative year, the team at Global Pricing Innovations (GPI) find ourselves both reflective and incredibly excited. 2024 has been a remarkable journey of innovation, technological advancement, and unprecedented growth in the pricing and market access domain.